B7-H4 (human):Fc (human) (rec.)
|Synonyms||V-set Domain-containing T Cell Activation Inhibitor 1; VTCN1; B7h.5; Immune Costimulatory Protein B7-H4; T Cell Costimulatory Molecule B7x; Protein B7S1|
The extracellular domain of human B7-H4 (aa 29-258) is fused to the N-terminus of the Fc region of human IgG1.
Measured by the ablility to inhibit anti-CD3-induced proliferation of stimulated human T cells. Human T lymphocytes cultured for 72 hours with PHA were incubated for an additional 3 days in 96 well place coated with 500ng/ml anti-CD3 and 10μg/ml human B7H4/Fc. The presence of human B7H4/Fc at 10μg/ml inhibited anti CD3 response by 30-50%. Optimal dilutions should be determined by each laboratory for each application.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
|Reconstitution||Reconstitute with 100 µl sterile water. Add 1X PBS to the desired protein concentration.|
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
NCBI reference NP_078902.2: B7-H4 (human)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
B7-H4 is a B7 family member that negatively regulates T cell immunity by inhibiting of T cell proliferation, cytokine production, and cell cycle progression. In vitro, B7-H4 inhibits CD4+ and CD8+ T cell proliferation, cytokine production, and generation of alloreactive cytotoxic T-cells (CTLs). In vivo, blockade of endogenous B7-H4 by specific monoclonal antibody promotes T cell responses. B7-H4 ia an important negative regulator of innate immunity through growth inhibition of neutrophils. B7-H4 is expressed on some tumor cancer cells. The role of B7-H4 in tumor progression may be to transform precancerous cells and then protect them from immunosurveillance.